Find My Journal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Tina Albertson, Jacob Garcia, Ana Kostić, Mary Mallaney, K. OGASAWARA, Kathryn J. Newhall, Yeonhee Kim, D. Li, Tanya Siddiqi

The Lancet, 2020

Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University, University of Nebraska Medical Center, The University of Texas MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, University of Alabama at Birmingham, University of Colorado Denver, Fred Hutch Cancer Center, University of California, San Francisco, University of Pittsburgh Medical Center, UPMC Hillman Cancer Center, Northside Hospital, Levine Cancer Institute, Bristol-Myers Squibb (United States), City Of Hope National Medical Center

Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

2270

Citations

View on Google Scholar